CN100438870C - ω干扰素在制备治疗温血动物对象中病毒性疾病的药物中的用途 - Google Patents

ω干扰素在制备治疗温血动物对象中病毒性疾病的药物中的用途 Download PDF

Info

Publication number
CN100438870C
CN100438870C CNB028245261A CN02824526A CN100438870C CN 100438870 C CN100438870 C CN 100438870C CN B028245261 A CNB028245261 A CN B028245261A CN 02824526 A CN02824526 A CN 02824526A CN 100438870 C CN100438870 C CN 100438870C
Authority
CN
China
Prior art keywords
interferon
purposes
omega interferon
omega
ifn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB028245261A
Other languages
English (en)
Chinese (zh)
Other versions
CN1635886A (zh
Inventor
M·S·莫兰
P·兰格克尔
D·G·布兰彻特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intarcia Therapeutics Inc
Original Assignee
Intarcia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intarcia Therapeutics Inc filed Critical Intarcia Therapeutics Inc
Publication of CN1635886A publication Critical patent/CN1635886A/zh
Application granted granted Critical
Publication of CN100438870C publication Critical patent/CN100438870C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNB028245261A 2001-11-09 2002-11-08 ω干扰素在制备治疗温血动物对象中病毒性疾病的药物中的用途 Expired - Fee Related CN100438870C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33794801P 2001-11-09 2001-11-09
US60/337,948 2001-11-09

Publications (2)

Publication Number Publication Date
CN1635886A CN1635886A (zh) 2005-07-06
CN100438870C true CN100438870C (zh) 2008-12-03

Family

ID=27662937

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB028245261A Expired - Fee Related CN100438870C (zh) 2001-11-09 2002-11-08 ω干扰素在制备治疗温血动物对象中病毒性疾病的药物中的用途

Country Status (12)

Country Link
US (2) US20030143197A1 (enExample)
EP (1) EP1536839B1 (enExample)
JP (1) JP2005516041A (enExample)
KR (1) KR20040053291A (enExample)
CN (1) CN100438870C (enExample)
AT (1) ATE481135T1 (enExample)
AU (1) AU2002365436B8 (enExample)
CA (1) CA2466228A1 (enExample)
DE (1) DE60237721D1 (enExample)
IL (2) IL161889A0 (enExample)
NZ (1) NZ532779A (enExample)
WO (1) WO2003063573A2 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
OA12835A (fr) * 2003-10-29 2006-09-15 Koung Nee Bellet Anne Brigitte Dr Interferon omega contre le VIH/SIDA, le cancer et asthme humain et veterinaire.
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
ATE481963T1 (de) 2006-05-30 2010-10-15 Intarcia Therapeutics Inc Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
AU2007284759B2 (en) 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
MX2009011123A (es) 2007-04-23 2009-11-02 Intarcia Therapeutics Inc Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
KR102093612B1 (ko) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 실질 항정상태 약물 전달의 신속 확립 및/또는 종결
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
KR102650751B1 (ko) 2015-06-03 2024-03-22 인타르시아 세라퓨틱스 인코포레이티드 임플란트 배치 및 제거 시스템들
CA3024479A1 (en) 2016-05-16 2017-11-23 Intarcia Therapeutics, Inc. Glucagon-receptor selective polypeptides and methods of use thereof
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
MX2019008006A (es) 2017-01-03 2019-08-29 Intarcia Therapeutics Inc Metodos que comprenden la administracion continua de un agonista del receptor de glp-1 y la co-administracion de un farmaco.
CN111973600B (zh) * 2020-08-20 2021-11-16 华中农业大学 霉酚酸或其衍生物在制备犬瘟热病毒抑制剂中的用途
WO2024015586A1 (en) * 2022-07-15 2024-01-18 Whitehead Institute For Biomedical Research Compositions and methods for treating cancer with interferon-omega and analogs thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231176A (en) * 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
WO2000040273A2 (en) * 1999-01-08 2000-07-13 Vical Incorporated Treatment of viral diseases using an interferon omega expressing polynucleotide
CN1309568A (zh) * 1998-05-15 2001-08-22 先灵公司 给首次接受抗病毒疗法的G慢性丙型肝炎感染患者施用包括利巴韦林和α干扰素的联合疗法

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
AU561343B2 (en) * 1981-10-19 1987-05-07 Genentech Inc. Human immune interferon by recombinant dna
DE3273597D1 (en) * 1981-11-28 1986-11-06 Sunstar Kk Pharmaceutical composition containing interferon in stable state
US5004689A (en) * 1982-02-22 1991-04-02 Biogen, Massachusetts DNA sequences, recombinant DNA molecules and processes for producing human gamma interferon-like polypeptides in high yields
US6936694B1 (en) * 1982-05-06 2005-08-30 Intermune, Inc. Manufacture and expression of large structural genes
DE3220116A1 (de) * 1982-05-28 1983-12-01 Dr. Karl Thomae Gmbh, 7950 Biberach Mikrobiologisch hergestellte (alpha)- und ss-interferone, dna-sequenzen, die fuer diese interferone codieren, mikroorganismen, die diese genetische information enthalten, und verfahren zu ihrer herstellung
US4966843A (en) * 1982-11-01 1990-10-30 Cetus Corporation Expression of interferon genes in Chinese hamster ovary cells
US4673405A (en) * 1983-03-04 1987-06-16 Alza Corporation Osmotic system with instant drug availability
MX9203641A (es) * 1983-12-16 1992-07-01 Genentech Inc Interferones gamma recombinantes que poseen estabilidad mejorada y metodos biotecnologicos para su obtencion.
US4855238A (en) * 1983-12-16 1989-08-08 Genentech, Inc. Recombinant gamma interferons having enhanced stability and methods therefor
US5120832A (en) * 1984-08-27 1992-06-09 Genentech, Inc. Distinct family of human leukocyte interferons
FI90990C (fi) * 1984-12-18 1994-04-25 Boehringer Ingelheim Int Rekombinantti-DNA-molekyyli, transformoitu isäntäorganismi ja menetelmä interferonin valmistamiseksi
ATE78262T1 (de) * 1985-06-11 1992-08-15 Ciba Geigy Ag Hybrid-interferone.
US4845196A (en) * 1985-06-24 1989-07-04 G. D. Searle & Co. Modified interferon gammas
US4847079A (en) * 1985-07-29 1989-07-11 Schering Corporation Biologically stable interferon compositions comprising thimerosal
DE3607835A1 (de) * 1986-03-10 1987-09-24 Boehringer Ingelheim Int Hybridinterferone, deren verwendung als arzneimittel und als zwischenprodukte zur herstellung von antikoerpern und deren verwendung sowie verfahren zu ihrer herstellung
CA1320905C (en) * 1986-11-06 1993-08-03 Joseph M. Cummins Treatment of immuno-resistant disease
ZA878295B (en) * 1986-11-06 1988-05-03 Amarillo Cell Culture Co. Inc. Treatment of immuno-resistant disease
DE3642096A1 (de) * 1986-12-10 1988-06-16 Boehringer Ingelheim Int Pferde-(gamma)-interferon
US4915954A (en) * 1987-09-03 1990-04-10 Alza Corporation Dosage form for delivering a drug at two different rates
US4917895A (en) * 1987-11-02 1990-04-17 Alza Corporation Transdermal drug delivery device
US4976966A (en) * 1988-12-29 1990-12-11 Alza Corporation Delayed release osmotically driven fluid dispenser
US5906816A (en) * 1995-03-16 1999-05-25 University Of Florida Method for treatment of autoimmune diseases
US5705363A (en) * 1989-03-02 1998-01-06 The Women's Research Institute Recombinant production of human interferon τ polypeptides and nucleic acids
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5223266A (en) * 1990-01-24 1993-06-29 Alza Corporation Long-term delivery device with early startup
US5120306A (en) * 1990-03-21 1992-06-09 Gosselin Leon F Direct delivery of anti-inflammatories to the proximal small bowel
US5207752A (en) * 1990-03-30 1993-05-04 Alza Corporation Iontophoretic drug delivery system with two-stage delivery profile
US5324280A (en) * 1990-04-02 1994-06-28 Alza Corporation Osmotic dosage system for delivering a formulation comprising liquid carrier and drug
US5529914A (en) * 1990-10-15 1996-06-25 The Board Of Regents The Univeristy Of Texas System Gels for encapsulation of biological materials
WO1992011843A1 (en) * 1991-01-09 1992-07-23 Alza Corporation Bioerodible devices and compositions for diffusional release of agents
US5443459A (en) * 1991-01-30 1995-08-22 Alza Corporation Osmotic device for delayed delivery of agent
US5676942A (en) * 1992-02-10 1997-10-14 Interferon Sciences, Inc. Composition containing human alpha interferon species proteins and method for use thereof
US5573934A (en) * 1992-04-20 1996-11-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5221278A (en) * 1992-03-12 1993-06-22 Alza Corporation Osmotically driven delivery device with expandable orifice for pulsatile delivery effect
FR2690622B1 (fr) * 1992-04-29 1995-01-20 Chronotec Système de pompe à perfusion ambulatoire programmable.
US5805688A (en) * 1993-04-01 1998-09-08 U.S. West Advanced Technologies, Inc. Automated system and method for call handling
DK0741577T3 (da) * 1994-03-07 2003-02-17 Imperial College Anvendelsen af enterferon, subtype alfa 8, til fremstilling af lægemidler til behandling af virusinfektioner i leveren
US5939286A (en) * 1995-05-10 1999-08-17 University Of Florida Hybrid interferon tau/alpha polypeptides, their recombinant production, and methods using them
US6129761A (en) * 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US5908621A (en) * 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
ES2246004T3 (es) * 1996-02-02 2006-02-01 Alza Corporation Liberacion prolongada de un agente activo usando un sistema implantable.
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
AU728146B2 (en) * 1996-03-14 2001-01-04 Immune Response Corporation, The Targeted delivery of genes encoding interferon
US6204022B1 (en) * 1996-04-12 2001-03-20 Pepgen Corporation And University Of Florida Low-toxicity human interferon-alpha analogs
ATE297741T1 (de) * 1997-04-07 2005-07-15 Iams Company Verfahren zur verbesserung des glukosemetabolismus, sättigungsgefühles, und nährstoffabsorption in haustieren
US6172046B1 (en) * 1997-09-21 2001-01-09 Schering Corporation Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection
EP1736145B1 (en) * 1997-12-30 2011-12-21 Intarcia Therapeutics, Inc Beneficial agent delivery system with membrane plug
TW586944B (en) * 1998-05-29 2004-05-11 Sumitomo Pharma Controlled release agent having a multi-layer structure
US7390637B2 (en) * 1998-07-21 2008-06-24 Human Genome Sciences, Inc. Keratinocyte derived interferon
US6472512B1 (en) * 1998-07-21 2002-10-29 Human Genome Sciences, Inc. Keratinocyte derived interferon
US6833256B1 (en) * 1999-06-22 2004-12-21 University Of Maryland Interferon tau mutants and methods for making them
US6436091B1 (en) * 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
US6875748B2 (en) * 2000-04-21 2005-04-05 Vical Incorporated Compositions and methods for in vivo delivery of polynucleotide-based therapeutics
WO2002036072A2 (en) * 2000-11-03 2002-05-10 Biomedicines, Inc. Method for short-term and long-term drug dosimetry

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5231176A (en) * 1984-08-27 1993-07-27 Genentech, Inc. Distinct family DNA encoding of human leukocyte interferons
CN1309568A (zh) * 1998-05-15 2001-08-22 先灵公司 给首次接受抗病毒疗法的G慢性丙型肝炎感染患者施用包括利巴韦林和α干扰素的联合疗法
WO2000040273A2 (en) * 1999-01-08 2000-07-13 Vical Incorporated Treatment of viral diseases using an interferon omega expressing polynucleotide

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
Antitumor effects of interferon-omega: in vivo therapy ofhuman tumor xenograft in nude mice. HORTON H.M.:.CANCER RESEARCH,Vol.59 . 1999
Antitumor effects of interferon-omega: in vivo therapy ofhuman tumor xenograft in nude mice. HORTON H.M.:.CANCER RESEARCH,Vol.59. 1999 *
不同剂量干扰素治疗乙肝病毒携带者150例疗效观察. 张金华.当代医生杂志，第2卷第12期. 1997
不同剂量干扰素治疗乙肝病毒携带者150例疗效观察. 张金华.当代医生杂志，第2卷第12期. 1997 *
不同剂量干扰素治疗病毒性脑炎疗效对比观察. 郑敏翠等.九江医学，第13卷第2期. 1998
不同剂量干扰素治疗病毒性脑炎疗效对比观察. 郑敏翠等.九江医学，第13卷第2期. 1998 *
大剂量干扰素治疗病毒性脑炎30例报告. 张春秀等.临床儿科杂志，第14卷第2期. 1996
大剂量干扰素治疗病毒性脑炎30例报告. 张春秀等.临床儿科杂志，第14卷第2期. 1996 *
阿昔洛韦、干扰素治疗小儿病毒性脑炎30例疗效观察. 陈衍杰等.荷泽医专学报，第12卷第1期. 2000
阿昔洛韦、干扰素治疗小儿病毒性脑炎30例疗效观察. 陈衍杰等.荷泽医专学报，第12卷第1期. 2000 *

Also Published As

Publication number Publication date
IL161889A (en) 2010-05-31
DE60237721D1 (de) 2010-10-28
US20030143197A1 (en) 2003-07-31
EP1536839A4 (en) 2009-03-11
AU2002365436B8 (en) 2008-04-03
EP1536839A2 (en) 2005-06-08
HK1084862A1 (zh) 2006-08-11
EP1536839B1 (en) 2010-09-15
CA2466228A1 (en) 2003-08-07
JP2005516041A (ja) 2005-06-02
WO2003063573A3 (en) 2005-04-14
KR20040053291A (ko) 2004-06-23
WO2003063573A2 (en) 2003-08-07
NZ532779A (en) 2008-04-30
ATE481135T1 (de) 2010-10-15
CN1635886A (zh) 2005-07-06
AU2002365436B2 (en) 2008-01-24
US20070248572A1 (en) 2007-10-25
IL161889A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
CN100438870C (zh) ω干扰素在制备治疗温血动物对象中病毒性疾病的药物中的用途
TWI241913B (en) Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis C
US20020127203A1 (en) Ribavirin-pegylated interferon alfa HCV combination therapy
DE60018273T2 (de) Pegyliertes interferon alpha in kombination mit einem ccr5 antagonisten für eine hiv-therapie
AU2002365436A1 (en) Method for treating diseases with omega interferon
CN1355708A (zh) 包含利巴韦林与抗氧化剂的hcv联合治疗
US20110270212A1 (en) Pharmacokinetic control for optimized interferon delivery
US6849254B1 (en) HCV combination therapy
US20110027229A1 (en) Continuous subcutaneous administration of interferon-alpha to hepatitis c infected patients
CN103071147A (zh) 干扰素-α向乙型肝炎感染的患者的连续皮下施用
CN103917240A (zh) Hcv免疫疗法
Soza et al. Pilot study of interferon gamma for chronic hepatitis C
WO2005062949A2 (en) Method for treating hepatitis virus infection
PT1535623E (pt) Tratamento para carcinoma de células renais
AU2006326688A1 (en) Treatment of multiple sclerosis using interferon-tau
JP2000256211A (ja) Ｈｉｖ治療薬
HK1084862B (en) Use of omega interferon in the manufacturing of a medicament for treating viral disease in a warm-blooded animal subject
TWI271196B (en) CML therapy
US20090232769A1 (en) Pharmaceutical Composition For Treatment Of Blood Clotting Disorder
JP2001516725A (ja) 慢性Ｃ型肝炎症の処置のためのＩＦＮ−αとアマンタジンの使用
Min et al. Early hepatitis C viral RNA decline during therapy with interferon α-2B and ribavirin in patients with chronic hepatitis C without sustained response to prior interferon
Minami et al. Regulation of the gene for amphotropic retrovirus receptor in rat liver cells by hepatocyte growth factor and triiodothyronine
Sakagami et al. Recombinant human interleukin 2 treatment in patients with chronic hepatitis B virus infection
Minniti et al. Chronic HBV/HCV hepatitis in heart transplant (HTx) recipients: open α-IFN treatment
Jacobson et al. The Future Use of Interferon in the Treatment of Hepatitis C: New Formulations, New Combinations

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1084862

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1084862

Country of ref document: HK

C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20081203

Termination date: 20121108